Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

16.97EUR
11:35am EDT
Change (% chg)

€0.12 (+0.71%)
Prev Close
€16.85
Open
€17.08
Day's High
€17.52
Day's Low
€16.90
Volume
154,956
Avg. Vol
327,515
52-wk High
€44.20
52-wk Low
€7.59

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €1,956.98
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -5.32 -- --
ROI: -54.08 14.23 13.82
ROE: -57.09 15.46 15.24

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

Mar 06 2019

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

Feb 14 2019

Earnings vs. Estimates